Selected research
Market Outlook & Growth Opportunities
Global Therapeutic Radiopharmaceuticals Market Outlook and Growth Opportunities 2026
Market perspective
The global Therapeutic Radiopharmaceuticals market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for Therapeutic Radiopharmaceuticals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Therapeutic Radiopharmaceuticals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Therapeutic Radiopharmaceuticals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Therapeutic Radiopharmaceuticals market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Therapeutic Radiopharmaceuticals market include Aurobindo Pharma, China Isotope & Radiation, Curium Pharmaceuticals, Dongcheng, International Isotopes, Jubilant Radiopharma, Lantheus, Mundipharma and Q BioMed, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Therapeutic Radiopharmaceuticals market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Therapeutic Radiopharmaceuticals and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Therapeutic Radiopharmaceuticals sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Therapeutic Radiopharmaceuticals market size, projected growth trends, production technologies, key applications, and end-use industries.
Therapeutic Radiopharmaceuticals Segment by Company
Aurobindo Pharma
China Isotope & Radiation
Curium Pharmaceuticals
Dongcheng
International Isotopes
Jubilant Radiopharma
Lantheus
Mundipharma
Q BioMed
Bayer
Novartis
Therapeutic Radiopharmaceuticals Segment by Type
Lutetium-177
Radium-223
Iodine-131
Other
Therapeutic Radiopharmaceuticals Segment by Application
Bone Metastasis
Thyroid
Lymphoma
Other
Therapeutic Radiopharmaceuticals Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Therapeutic Radiopharmaceuticals status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Therapeutic Radiopharmaceuticals market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Therapeutic Radiopharmaceuticals significant trends, drivers, influence factors in global and regions.
6. To analyze Therapeutic Radiopharmaceuticals competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Therapeutic Radiopharmaceuticals market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Therapeutic Radiopharmaceuticals and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Therapeutic Radiopharmaceuticals.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Therapeutic Radiopharmaceuticals market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Therapeutic Radiopharmaceuticals industry.
Chapter 3: Detailed analysis of Therapeutic Radiopharmaceuticals manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Therapeutic Radiopharmaceuticals in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Therapeutic Radiopharmaceuticals in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
More report detail
Tables and figures
Scope & coverage.
Types
- Lutetium-177
- Radium-223
- Iodine-131
- Other
Applications
- Bone Metastasis
- Thyroid
- Lymphoma
- Other
Companies covered
- Aurobindo Pharma
- China Isotope & Radiation
- Curium Pharmaceuticals
- Dongcheng
- International Isotopes
- Jubilant Radiopharma
- Lantheus
- Mundipharma
- Q BioMed
- Bayer
- Novartis
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Therapeutic Radiopharmaceuticals Sales Value (2021-2032)
- 1.2.2 Global Therapeutic Radiopharmaceuticals Sales Volume (2021-2032)
- 1.2.3 Global Therapeutic Radiopharmaceuticals Sales Average Price (2021-2032)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
2 Therapeutic Radiopharmaceuticals Market Dynamics
- 2.1 Therapeutic Radiopharmaceuticals Industry Trends
- 2.2 Therapeutic Radiopharmaceuticals Industry Drivers
- 2.3 Therapeutic Radiopharmaceuticals Industry Opportunities and Challenges
- 2.4 Therapeutic Radiopharmaceuticals Industry Restraints
3 Therapeutic Radiopharmaceuticals Market by Company
- 3.1 Global Therapeutic Radiopharmaceuticals Company Revenue Ranking in 2025
- 3.2 Global Therapeutic Radiopharmaceuticals Revenue by Company (2021-2026)
- 3.3 Global Therapeutic Radiopharmaceuticals Sales Volume by Company (2021-2026)
- 3.4 Global Therapeutic Radiopharmaceuticals Average Price by Company (2021-2026)
- 3.5 Global Therapeutic Radiopharmaceuticals Company Ranking (2024-2026)
- 3.6 Global Therapeutic Radiopharmaceuticals Company Manufacturing Base and Headquarters
- 3.7 Global Therapeutic Radiopharmaceuticals Company Product Type and Application
- 3.8 Global Therapeutic Radiopharmaceuticals Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Therapeutic Radiopharmaceuticals Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.9.3 2025 Therapeutic Radiopharmaceuticals Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
4 Therapeutic Radiopharmaceuticals Market by Type
- 4.1 Therapeutic Radiopharmaceuticals Type Introduction
- 4.1.1 Lutetium-177
- 4.1.2 Radium-223
- 4.1.3 Iodine-131
- 4.1.4 Other
- 4.2 Global Therapeutic Radiopharmaceuticals Sales Volume by Type
- 4.2.1 Global Therapeutic Radiopharmaceuticals Sales Volume by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Therapeutic Radiopharmaceuticals Sales Volume by Type (2021-2032)
- 4.2.3 Global Therapeutic Radiopharmaceuticals Sales Volume Share by Type (2021-2032)
- 4.3 Global Therapeutic Radiopharmaceuticals Sales Value by Type
- 4.3.1 Global Therapeutic Radiopharmaceuticals Sales Value by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Therapeutic Radiopharmaceuticals Sales Value by Type (2021-2032)
- 4.3.3 Global Therapeutic Radiopharmaceuticals Sales Value Share by Type (2021-2032)
5 Therapeutic Radiopharmaceuticals Market by Application
- 5.1 Therapeutic Radiopharmaceuticals Application Introduction
- 5.1.1 Bone Metastasis
- 5.1.2 Thyroid
- 5.1.3 Lymphoma
- 5.1.4 Other
- 5.2 Global Therapeutic Radiopharmaceuticals Sales Volume by Application
- 5.2.1 Global Therapeutic Radiopharmaceuticals Sales Volume by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Therapeutic Radiopharmaceuticals Sales Volume by Application (2021-2032)
- 5.2.3 Global Therapeutic Radiopharmaceuticals Sales Volume Share by Application (2021-2032)
- 5.3 Global Therapeutic Radiopharmaceuticals Sales Value by Application
- 5.3.1 Global Therapeutic Radiopharmaceuticals Sales Value by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Therapeutic Radiopharmaceuticals Sales Value by Application (2021-2032)
- 5.3.3 Global Therapeutic Radiopharmaceuticals Sales Value Share by Application (2021-2032)
6 Therapeutic Radiopharmaceuticals Regional Sales and Value Analysis
- 6.1 Global Therapeutic Radiopharmaceuticals Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Therapeutic Radiopharmaceuticals Sales by Region (2021-2032)
- 6.2.1 Global Therapeutic Radiopharmaceuticals Sales by Region: 2021-2026
- 6.2.2 Global Therapeutic Radiopharmaceuticals Sales by Region (2027-2032)
- 6.3 Global Therapeutic Radiopharmaceuticals Sales Value by Region: 2021 VS 2025 VS 2032
- 6.4 Global Therapeutic Radiopharmaceuticals Sales Value by Region (2021-2032)
- 6.4.1 Global Therapeutic Radiopharmaceuticals Sales Value by Region: 2021-2026
- 6.4.2 Global Therapeutic Radiopharmaceuticals Sales Value by Region (2027-2032)
- 6.5 Global Therapeutic Radiopharmaceuticals Market Price Analysis by Region (2021-2026)
- 6.6 North America
- 6.6.1 North America Therapeutic Radiopharmaceuticals Sales Value (2021-2032)
- 6.6.2 North America Therapeutic Radiopharmaceuticals Sales Value Share by Country, 2025 VS 2032
- 6.7 Europe
- 6.7.1 Europe Therapeutic Radiopharmaceuticals Sales Value (2021-2032)
- 6.7.2 Europe Therapeutic Radiopharmaceuticals Sales Value Share by Country, 2025 VS 2032
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Therapeutic Radiopharmaceuticals Sales Value (2021-2032)
- 6.8.2 Asia-Pacific Therapeutic Radiopharmaceuticals Sales Value Share by Country, 2025 VS 2032
- 6.9 South America
- 6.9.1 South America Therapeutic Radiopharmaceuticals Sales Value (2021-2032)
- 6.9.2 South America Therapeutic Radiopharmaceuticals Sales Value Share by Country, 2025 VS 2032
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Therapeutic Radiopharmaceuticals Sales Value (2021-2032)
- 6.10.2 Middle East & Africa Therapeutic Radiopharmaceuticals Sales Value Share by Country, 2025 VS 2032
7 Therapeutic Radiopharmaceuticals Country-level Sales and Value Analysis
- 7.1 Global Therapeutic Radiopharmaceuticals Sales by Country: 2021 VS 2025 VS 2032
- 7.2 Global Therapeutic Radiopharmaceuticals Sales Value by Country: 2021 VS 2025 VS 2032
- 7.3 Global Therapeutic Radiopharmaceuticals Sales by Country (2021-2032)
- 7.3.1 Global Therapeutic Radiopharmaceuticals Sales by Country (2021-2026)
- 7.3.2 Global Therapeutic Radiopharmaceuticals Sales by Country (2027-2032)
- 7.4 Global Therapeutic Radiopharmaceuticals Sales Value by Country (2021-2032)
- 7.4.1 Global Therapeutic Radiopharmaceuticals Sales Value by Country (2021-2026)
- 7.4.2 Global Therapeutic Radiopharmaceuticals Sales Value by Country (2027-2032)
- 7.5 USA
- 7.5.1 USA Therapeutic Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
- 7.5.2 USA Therapeutic Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
- 7.5.3 USA Therapeutic Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
- 7.6 Canada
- 7.6.1 Canada Therapeutic Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
- 7.6.2 Canada Therapeutic Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Canada Therapeutic Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
- 7.7 Mexico
- 7.6.1 Mexico Therapeutic Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
- 7.6.2 Mexico Therapeutic Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Mexico Therapeutic Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
- 7.8 Germany
- 7.8.1 Germany Therapeutic Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
- 7.8.2 Germany Therapeutic Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
- 7.8.3 Germany Therapeutic Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
- 7.9 France
- 7.9.1 France Therapeutic Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
- 7.9.2 France Therapeutic Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
- 7.9.3 France Therapeutic Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
- 7.10 U.K.
- 7.10.1 U.K. Therapeutic Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
- 7.10.2 U.K. Therapeutic Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
- 7.10.3 U.K. Therapeutic Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
- 7.11 Italy
- 7.11.1 Italy Therapeutic Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
- 7.11.2 Italy Therapeutic Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Italy Therapeutic Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
- 7.12 Spain
- 7.12.1 Spain Therapeutic Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
- 7.12.2 Spain Therapeutic Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Spain Therapeutic Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
- 7.13 Russia
- 7.13.1 Russia Therapeutic Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
- 7.13.2 Russia Therapeutic Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Russia Therapeutic Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
- 7.14 Netherlands
- 7.14.1 Netherlands Therapeutic Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
- 7.14.2 Netherlands Therapeutic Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
- 7.14.3 Netherlands Therapeutic Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Therapeutic Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
- 7.15.2 Nordic Countries Therapeutic Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Nordic Countries Therapeutic Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
- 7.16 China
- 7.16.1 China Therapeutic Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
- 7.16.2 China Therapeutic Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
- 7.16.3 China Therapeutic Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
- 7.17 Japan
- 7.17.1 Japan Therapeutic Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
- 7.17.2 Japan Therapeutic Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
- 7.17.3 Japan Therapeutic Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
- 7.18 South Korea
- 7.18.1 South Korea Therapeutic Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
- 7.18.2 South Korea Therapeutic Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
- 7.18.3 South Korea Therapeutic Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
- 7.19 India
- 7.19.1 India Therapeutic Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
- 7.19.2 India Therapeutic Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
- 7.19.3 India Therapeutic Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
- 7.20 Australia
- 7.20.1 Australia Therapeutic Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
- 7.20.2 Australia Therapeutic Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Australia Therapeutic Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Therapeutic Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
- 7.21.2 Southeast Asia Therapeutic Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Southeast Asia Therapeutic Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
- 7.22 Brazil
- 7.22.1 Brazil Therapeutic Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
- 7.22.2 Brazil Therapeutic Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Brazil Therapeutic Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
- 7.23 Argentina
- 7.23.1 Argentina Therapeutic Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
- 7.23.2 Argentina Therapeutic Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Argentina Therapeutic Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
- 7.24 Chile
- 7.24.1 Chile Therapeutic Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
- 7.24.2 Chile Therapeutic Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Chile Therapeutic Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
- 7.25 Colombia
- 7.25.1 Colombia Therapeutic Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
- 7.25.2 Colombia Therapeutic Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Colombia Therapeutic Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
- 7.26 Peru
- 7.26.1 Peru Therapeutic Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
- 7.26.2 Peru Therapeutic Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Peru Therapeutic Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Therapeutic Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
- 7.27.2 Saudi Arabia Therapeutic Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
- 7.27.3 Saudi Arabia Therapeutic Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
- 7.28 Israel
- 7.28.1 Israel Therapeutic Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
- 7.28.2 Israel Therapeutic Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Israel Therapeutic Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
- 7.29 UAE
- 7.29.1 UAE Therapeutic Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
- 7.29.2 UAE Therapeutic Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
- 7.29.3 UAE Therapeutic Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
- 7.30 Turkey
- 7.30.1 Turkey Therapeutic Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
- 7.30.2 Turkey Therapeutic Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Turkey Therapeutic Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
- 7.31 Iran
- 7.31.1 Iran Therapeutic Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
- 7.31.2 Iran Therapeutic Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
- 7.31.3 Iran Therapeutic Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
- 7.32 Egypt
- 7.32.1 Egypt Therapeutic Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
- 7.32.2 Egypt Therapeutic Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
- 7.32.3 Egypt Therapeutic Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 Aurobindo Pharma
- 8.1.1 Aurobindo Pharma Company Information
- 8.1.2 Aurobindo Pharma Business Overview
- 8.1.3 Aurobindo Pharma Therapeutic Radiopharmaceuticals Sales, Value and Gross Margin (2021-2026)
- 8.1.4 Aurobindo Pharma Therapeutic Radiopharmaceuticals Product Portfolio
- 8.1.5 Aurobindo Pharma Recent Developments
- 8.2 China Isotope & Radiation
- 8.2.1 China Isotope & Radiation Company Information
- 8.2.2 China Isotope & Radiation Business Overview
- 8.2.3 China Isotope & Radiation Therapeutic Radiopharmaceuticals Sales, Value and Gross Margin (2021-2026)
- 8.2.4 China Isotope & Radiation Therapeutic Radiopharmaceuticals Product Portfolio
- 8.2.5 China Isotope & Radiation Recent Developments
- 8.3 Curium Pharmaceuticals
- 8.3.1 Curium Pharmaceuticals Company Information
- 8.3.2 Curium Pharmaceuticals Business Overview
- 8.3.3 Curium Pharmaceuticals Therapeutic Radiopharmaceuticals Sales, Value and Gross Margin (2021-2026)
- 8.3.4 Curium Pharmaceuticals Therapeutic Radiopharmaceuticals Product Portfolio
- 8.3.5 Curium Pharmaceuticals Recent Developments
- 8.4 Dongcheng
- 8.4.1 Dongcheng Company Information
- 8.4.2 Dongcheng Business Overview
- 8.4.3 Dongcheng Therapeutic Radiopharmaceuticals Sales, Value and Gross Margin (2021-2026)
- 8.4.4 Dongcheng Therapeutic Radiopharmaceuticals Product Portfolio
- 8.4.5 Dongcheng Recent Developments
- 8.5 International Isotopes
- 8.5.1 International Isotopes Company Information
- 8.5.2 International Isotopes Business Overview
- 8.5.3 International Isotopes Therapeutic Radiopharmaceuticals Sales, Value and Gross Margin (2021-2026)
- 8.5.4 International Isotopes Therapeutic Radiopharmaceuticals Product Portfolio
- 8.5.5 International Isotopes Recent Developments
- 8.6 Jubilant Radiopharma
- 8.6.1 Jubilant Radiopharma Company Information
- 8.6.2 Jubilant Radiopharma Business Overview
- 8.6.3 Jubilant Radiopharma Therapeutic Radiopharmaceuticals Sales, Value and Gross Margin (2021-2026)
- 8.6.4 Jubilant Radiopharma Therapeutic Radiopharmaceuticals Product Portfolio
- 8.6.5 Jubilant Radiopharma Recent Developments
- 8.7 Lantheus
- 8.7.1 Lantheus Company Information
- 8.7.2 Lantheus Business Overview
- 8.7.3 Lantheus Therapeutic Radiopharmaceuticals Sales, Value and Gross Margin (2021-2026)
- 8.7.4 Lantheus Therapeutic Radiopharmaceuticals Product Portfolio
- 8.7.5 Lantheus Recent Developments
- 8.8 Mundipharma
- 8.8.1 Mundipharma Company Information
- 8.8.2 Mundipharma Business Overview
- 8.8.3 Mundipharma Therapeutic Radiopharmaceuticals Sales, Value and Gross Margin (2021-2026)
- 8.8.4 Mundipharma Therapeutic Radiopharmaceuticals Product Portfolio
- 8.8.5 Mundipharma Recent Developments
- 8.9 Q BioMed
- 8.9.1 Q BioMed Company Information
- 8.9.2 Q BioMed Business Overview
- 8.9.3 Q BioMed Therapeutic Radiopharmaceuticals Sales, Value and Gross Margin (2021-2026)
- 8.9.4 Q BioMed Therapeutic Radiopharmaceuticals Product Portfolio
- 8.9.5 Q BioMed Recent Developments
- 8.10 Bayer
- 8.10.1 Bayer Company Information
- 8.10.2 Bayer Business Overview
- 8.10.3 Bayer Therapeutic Radiopharmaceuticals Sales, Value and Gross Margin (2021-2026)
- 8.10.4 Bayer Therapeutic Radiopharmaceuticals Product Portfolio
- 8.10.5 Bayer Recent Developments
- 8.11 Novartis
- 8.11.1 Novartis Company Information
- 8.11.2 Novartis Business Overview
- 8.11.3 Novartis Therapeutic Radiopharmaceuticals Sales, Value and Gross Margin (2021-2026)
- 8.11.4 Novartis Therapeutic Radiopharmaceuticals Product Portfolio
- 8.11.5 Novartis Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Therapeutic Radiopharmaceuticals Value Chain Analysis
- 9.1.1 Therapeutic Radiopharmaceuticals Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Therapeutic Radiopharmaceuticals Sales Mode & Process
- 9.2 Therapeutic Radiopharmaceuticals Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Therapeutic Radiopharmaceuticals Distributors
- 9.2.3 Therapeutic Radiopharmaceuticals Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst